Clinical Trials Browser

Completed × Carcinoma, Non-Small-Cell Lung × cabozantinib × Clear all

Carcinoma, Non-Small-Cell Lung

NCT00940225 2024-04-25

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT02795156 2023-12-05

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

Phase 2 Completed

100 enrolled 14 charts

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT02071862 2022-07-20

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Phase 1 Completed

210 enrolled

BreastGenitourinaryOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Mesothelioma, Triple Negative Breast Neoplasms

NCT01866410 2019-05-16

Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer

Phase 2 Completed

37 enrolled 13 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

CONTACT-01

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer